Shenyang Northern Hospital is the lead sponsor of 9 current clinical trials in our China register. 4 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Dapagliflozin. The most-studied condition is Acute Coronary Syndrome (ACS).
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Clinical Outcomes of Patients With Coronary Artery Disease
NCT06216847 · ClinicalTrials.gov ↗ · Coronary Heart Disease (CHD)
|
Observational | Recruiting | 2024-02 | China |
|
Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis
NCT07362966 · ClinicalTrials.gov ↗ · Colchicine, Coronary Atherosclerosis Management, Clonal Hematopoiesis of Indeterminate Potential
|
Phase 4 | Recruiting | 2026-06 | China |
|
Early Thrombolysis Guided by AI-Assisted App in Patients With STEMI
NCT07160491 · ClinicalTrials.gov ↗ · STEMI - ST Elevation Myocardial Infarction
|
Not applicable | Recruiting | 2025-09 | China |
|
OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time
NCT06216821 · ClinicalTrials.gov ↗ · Acute Coronary Syndrome
|
Not applicable | Recruiting | 2024-07 | China |
|
OCT or Angiography Guided De-escalation of DAPT
NCT06339021 · ClinicalTrials.gov ↗ · Optical Coherence Tomography, Dual Antiplatelet Therapy, Antiplatelet De-escalation
|
Phase EARLY_PHASE1 | Not yet open | 2024-04 | China |
|
Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy
NCT07354828 · ClinicalTrials.gov ↗ · Acute Coronary Syndrome (ACS), High Bleeding Risk (HBR), Coronary Artery Disease (CAD)
|
Observational | Not yet open | 2025-12 | China |
|
CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF
NCT07351643 · ClinicalTrials.gov ↗ · ACS (Acute Coronary Syndrome), SGLT2 Inhibitors
Drug: Dapagliflozin |
Phase 4 | Not yet open | 2026-02 | China |
|
Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk
NCT07374718 · ClinicalTrials.gov ↗ · Acute Coronary Syndrome (ACS), High Bleeding Risk(HBR), Coronary Artery Disease (CAD)
|
Not applicable | Not yet open | 2026-03 | China |
|
SGLT2-inhibitors on PC-AKI
NCT06491953 · ClinicalTrials.gov ↗ · Impact of SGLT2-inhibitors on PC-AKI in ACS Patients Receiving Invasive Strategy
|
Observational | Active, closed | 2024-06 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 9 | 4 |
A trial with sites in more than one country appears in each of those registers.
Shenyang Northern Hospital is the lead sponsor of 9 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of its 9 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 1 drug or biological as interventions. The most frequent are Dapagliflozin (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.